Suppr超能文献

趋化因子受体 CXCR4 对缺氧诱导的大鼠肺动脉高压和血管重构的影响。

Effect of chemokine receptor CXCR4 on hypoxia-induced pulmonary hypertension and vascular remodeling in rats.

机构信息

Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

出版信息

Respir Res. 2011 Feb 4;12(1):21. doi: 10.1186/1465-9921-12-21.

Abstract

BACKGROUND

CXCR4 is the receptor for chemokine CXCL12 and reportedly plays an important role in systemic vascular repair and remodeling, but the role of CXCR4 in development of pulmonary hypertension and vascular remodeling has not been fully understood.

METHODS

In this study we investigated the role of CXCR4 in the development of pulmonary hypertension and vascular remodeling by using a CXCR4 inhibitor AMD3100 and by electroporation of CXCR4 shRNA into bone marrow cells and then transplantation of the bone marrow cells into rats.

RESULTS

We found that the CXCR4 inhibitor significantly decreased chronic hypoxia-induced pulmonary hypertension and vascular remodeling in rats and, most importantly, we found that the rats that were transplanted with the bone marrow cells electroporated with CXCR4 shRNA had significantly lower mean pulmonary pressure (mPAP), ratio of right ventricular weight to left ventricular plus septal weight (RV/(LV+S)) and wall thickness of pulmonary artery induced by chronic hypoxia as compared with control rats.

CONCLUSIONS

The hypothesis that CXCR4 is critical in hypoxic pulmonary hypertension in rats has been demonstrated. The present study not only has shown an inhibitory effect caused by systemic inhibition of CXCR4 activity on pulmonary hypertension, but more importantly also has revealed that specific inhibition of the CXCR4 in bone marrow cells can reduce pulmonary hypertension and vascular remodeling via decreasing bone marrow derived cell recruitment to the lung in hypoxia. This study suggests a novel therapeutic approach for pulmonary hypertension by inhibiting bone marrow derived cell recruitment.

摘要

背景

趋化因子受体 4(CXCR4)是趋化因子 CXCL12 的受体,据报道在系统性血管修复和重塑中发挥重要作用,但 CXCR4 在肺动脉高压和血管重塑发展中的作用尚未完全阐明。

方法

在这项研究中,我们通过使用 CXCR4 抑制剂 AMD3100 以及用电穿孔将 CXCR4 shRNA 转染到骨髓细胞中,然后将骨髓细胞移植到大鼠体内,来研究 CXCR4 在肺动脉高压和血管重塑发展中的作用。

结果

我们发现 CXCR4 抑制剂显著降低了慢性缺氧诱导的大鼠肺动脉高压和血管重塑,最重要的是,我们发现与对照组大鼠相比,用 CXCR4 shRNA 电穿孔转染的骨髓细胞移植的大鼠的平均肺动脉压(mPAP)、右心室重量与左心室加室间隔重量的比值(RV/(LV+S))和慢性缺氧诱导的肺动脉壁厚度明显降低。

结论

已经证明了 CXCR4 在大鼠缺氧性肺动脉高压中至关重要的假说。本研究不仅显示了系统抑制 CXCR4 活性对肺动脉高压的抑制作用,而且更重要的是还表明,特异性抑制骨髓细胞中的 CXCR4 可以通过减少骨髓源性细胞在缺氧时向肺部的募集来减轻肺动脉高压和血管重塑。这项研究通过抑制骨髓源性细胞募集为肺动脉高压提供了一种新的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d42/3042398/303b784ce181/1465-9921-12-21-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验